HUTCHMED (China) Limited (FRA:H7T1)

Market Cap	2.24B -0.6%
Revenue (ttm)	480.65M -8.8%
Net Income	15.65M -96.2%
EPS	0.09 -96.2%
Shares Out	n/a
PE Ratio	137.62
Forward PE	39.26
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	12.50
Previous Close	12.40
Day's Range	12.50 - 12.50
52-Week Range	8.45 - 13.50
Beta	n/a
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 13, 2026

About HUTCHMED (China)

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), endomet...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2000
• Employees: 1,790
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: H7T1

Financial Performance

In 2025, HUTCHMED (China)'s revenue was $548.51 million, a decrease of -12.96% compared to the previous year's $630.20 million. Earnings were $456.91 million, an increase of 1111.03%.

Financial numbers in USD

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Oct 25, 2026

Data Sources Report a data error